Author:
Watson Felicia N.,Shears Melanie J.,Kalata Anya C.,Duncombe Caroline J.,Seilie A. Mariko,Chavtur Chris,Conrad Ethan,Cruz Talavera Irene,Raappana Andrew,Sather D. Noah,Chakravarty Sumana,Sim B. Kim Lee,Hoffman Stephen L.,Tsuji Moriya,Murphy Sean C.
Abstract
AbstractRadiation-attenuated sporozoite (RAS) vaccines can completely prevent blood stage Plasmodium infection by inducing liver-resident memory CD8+ T cells to target parasites in the liver. Such T cells can be induced by ‘Prime-and-trap’ vaccination, which here combines DNA priming against the P. yoelii circumsporozoite protein (CSP) with a subsequent intravenous (IV) dose of liver-homing RAS to “trap” the activated and expanding T cells in the liver. Prime-and-trap confers durable protection in mice, and efforts are underway to translate this vaccine strategy to the clinic. However, it is unclear whether the RAS trapping dose must be strictly administered by the IV route. Here we show that intradermal (ID) RAS administration can be as effective as IV administration if RAS are co-administrated with the glycolipid adjuvant 7DW8-5 in an ultra-low inoculation volume. In mice, the co-administration of RAS and 7DW8-5 in ultra-low ID volumes (2.5 µL) was completely protective and dose sparing compared to standard volumes (10–50 µL) and induced protective levels of CSP-specific CD8+ T cells in the liver. Our finding that adjuvants and ultra-low volumes are required for ID RAS efficacy may explain why prior reports about higher volumes of unadjuvanted ID RAS proved less effective than IV RAS. The ID route may offer significant translational advantages over the IV route and could improve sporozoite vaccine development.
Funder
National Institute of Allergy and Infectious Diseases,United States
National Institute of Allergy and Infectious Diseases
Publisher
Springer Science and Business Media LLC
Reference72 articles.
1. World Health Organization. World Malaria Report 2021. Geneva, Switzerland: World Health Organization; 2021 December 6, 2021.
2. Marques-da-Silva, C., Peissig, K. & Kurup, S. P. Pre-erythrocytic vaccines against malaria. Vaccines (Basel). 8(3) (2020).
3. Itsara, L. S. et al. The development of whole sporozoite vaccines for Plasmodium falciparum malaria. Front. Immunol. 9, 2748 (2018).
4. Seder, R. A. et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 341(6152), 1359–1365 (2013).
5. Richie, T. L. et al. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine. 33(52), 7452–7461 (2015).